Source: PR Newswire

Press Release: Soligenix : Soligenix Receives US Patent for Dusquetide Related Analogs

PRINCETON, N.J., April 4, 2019 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that the US...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Annual Revenue
Employees
Christopher J. Schaber's photo - President & CEO of Soligenix

President & CEO

Christopher J. Schaber

CEO Approval Rating

68/100

Soligenix develops and commercializes biotherapeutics for the treatment of gastrointestinal disorders, inflammation and oncology diseases. Read more